Role of lincRNA-p21 and lncRNA-H19 in multiple sclerosis disease / Laila Mahdi Mohamed Meber ; Supervised Olfat Gamil Shaker , Nermien Esmat Waly , Amr Hassan Elsayed
Material type:
- فى مرض التصلب المتعدد (lncRNA-H19 و lincRNA-p21)دور ا{uئإإ٠}{uئآ٧ؤ}ينات [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.03.Ph.D.2020.La.R (Browse shelf(Opens below)) | Not for loan | 01010110080812000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.03.Ph.D.2020.La.R (Browse shelf(Opens below)) | 80812.CD | Not for loan | 01020110080812000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Medical Biochemistry
Aims: Long non-coding RNAs (lncRNAs) were believed to play a role in the pathogenesis of many neurological disorders. The expression of two lncRNAs; lncRNA-H19 and lincRNA-p21 were investigated in patients with multiple sclerosis (MS) to clarify their role in MS pathogenesis and their impact on clinical course of the disease. Methods: This case-control study was conducted on 134 subjects; 74 patients with MS fulfilling the 2010 revised McDonald criteria and 60 healthy age- and sex- matched control. The clinical disability was evaluated using the expanded disability status scale (EDSS). Quantification of serum expression levels of the two studied lncRNAs was performed by real-time quantitative polymerase chain reaction (qPCR). Results: LncRNA-H19 was found to be significantly down-regulated in serum samples from MS patients compared to control group (p-value= 0.024). It was significantly higher in male patients as compared to female patients (p-value= 0.008). LincRNA-P21 was found to be significantly down-regulated in serum samples from MS patients compared with the control group; (p= 0.020). Patients with EDSS {u2265} 5.5 had significantly higher expression level of lincRNA-P21 than those with EDSS=1-3 (p= 0.027).There was significantly higher expression level of lincRNA-P21 among patients who received cyclophosphamide (immunosuppressant) than those who received interferon (p= 0.005)
Issued also as CD
There are no comments on this title.